Cited by 283Telomeres, Telomerase, and SenescenceGenomics and Chromatin DynamicsGenetics, Aging, and Longevity in Model Organisms

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index; none of the 32 sources its claims cite is checked for support yet.

Senescence-associated heterochromatin foci are dispensable for cellular senescence, occur in a cell type- and insult-dependent manner and follow expression of p16ink4a

Open access
Kosar, Martin, Bartkova, Jirina, Hubackova, Sona, Hodny, Zdenek, Lukas, Jiri, Bartek, Jiri·2011·Cell Cycle

Abstract

Cellular senescence, an irreversible proliferation arrest evoked by stresses such as oncogene activation, telomere dysfunction, or diverse genotoxic insults, has been implicated in tumor suppression and aging. Primary human fibroblasts undergoing oncogene-induced or replicative senescence are known to form senescence-associated heterochromatin foci (SAHF), nuclear DNA domains stained densely by DAPI and enriched for histone modifications including lysine9-trimethylated histone H3. While cellular senescence occurs also in premalignant human lesions, it is unclear how universal is SAHF formation among various cell types, under diverse stresses, and whether SAHF occur in vivo. Here, we report that human primary fibroblasts (BJ and MRC-5) and primary keratinocytes undergoing replicative senescence, or premature senescence induced by oncogenic H-Ras, diverse chemotherapeutics and bacterial cytolethal distending toxin, show differential capacity to form SAHF. Whereas all tested cell types formed SAHF in response to activated H-Ras, only MRC-5, but not BJ fibroblasts or keratinocytes, formed SAHF under senescence induced by etoposide, doxorubicin, hydroxyurea, bacterial intoxication or telomere attrition. In addition, DAPI-defined SAHF were detected on paraffin sections of Ras-transformed cultured fibroblasts, but not human lesions at various stages of tumorigenesis. Overall, our results indicate that unlike the widely present DNA damage response marker γH2AX, SAHF is not a common feature of cellular senescence. Whereas SAHF formation is shared by diverse cultured cell types under oncogenic stress, SAHF are cell-type-restricted under genotoxin-induced and replicative senescence. Furthermore, while the DNA/DAPI-defined SAHF formation in cultured cells parallels enhanced expression of p16(ink4a) , such 'prototypic' SAHF are not observed in tissues, including premalignant lesions, irrespective of enhanced p16(ink4a) and other features of cellular senescence.

Overview

Integrity signals

Registry

Crossref · 10.4161/cc.10.3.14707

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 of 32 cited sources checked · 0 supported · 0 flagged

Show all 32 claims

  • It may state two separate claims as one. 22
  • The quote only partly states this claim. 1
  • Probably not a substantial claim. 10
28 of 28
  • The paper relies on this without support.

    p16ink4a protein abundance reflects activation of the p16ink4a-pRb pathway in the cells studied.

    “we argued that the observed differences might reflect variable levels of the p16 ink4a CDK inhibitor, and hence the activation of the pRb pathway, whose role in SAHF formation has been documented.4,38”
1 of 1

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

  • The bacterial-intoxication citation points to a drug study

    Minor

    Reference 42 is cited for a previously described mode of senescence induced by bacterial intoxication, but its listed article concerns DNA-damage-induced senescence in tumor cells.

  • Error bars are described as both confidence intervals and standard deviations

    Minor

    The statistics section says the results are shown with 95% confidence intervals, but the Figure 2 legend says its error bars show standard deviations. These are different measures of variability.

  • Holotoxin-preparation citations do not match the listed papers

    Minor

    The methods attribute preparation of the bacterial toxin subunits and holotoxin to references 47 and 75. The listed entries concern a tumorigenesis barrier and H2AX phosphorylation, respectively, rather than that preparation.

  • Reference 48 does not match the cited earlier study

    Minor

    The text attributes an earlier study of heterochromatin markers in premalignant lesions to reference 48. The listed reference 48 is instead a study of BMI-1026-induced SAHF formation by different authors.

4 of 4

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 18

  1. Narita M, Nunez S, Heard E, Lin AW, Hearn SA, Spector DL, et al. Rb-mediated heterochromatin for- mation and silencing of E2F target genes during cel- lular senescence. Cell 2003; 113:703-16.
  2. Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R, Desmet CJ, et al. Oncogene-induced senescence relayed by an interleukin-dependent inflam- matory network. Cell 2008; 133:1019-31.
  3. Sedelnikova OA, Horikawa I, Zimonjic DB, Popescu NC, Bonner WM, Barrett JC. Senescing human cells and ageing mice accumulate DNA lesions with unre- pairable double-strand breaks. Nat Cell Biol 2004; 6:168-70.
  4. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, et al. A DNA dam- age checkpoint response in telomere-initiated senes- cence. Nature 2003; 426:194-8.
  5. Gray-Schopfer VC, Cheong SC, Chong H, Chow J, Moss T, Abdel-Malek ZA, et al. Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br J Cancer 2006; 95:496-505.
  6. Brenner AJ, Stampfer MR, Aldaz CM. Increased p16 expression with first senescence arrest in human mam- mary epithelial cells and extended growth capacity with p16 inactivation. Oncogene 1998; 17:199-205.
  7. Bringold F, Serrano M. Tumor suppressors and onco- genes in cellular senescence. Exp Gerontol 2000; 35:317-29.
  8. Halazonetis TD, Gorgoulis VG, Bartek J. An onco- gene-induced DNA damage model for cancer develop- ment. Science 2008; 319:1352-5.
  9. Goodarzi AA, Noon AT, Jeggo PA. The impact of het- erochromatin on DSB repair. Biochem Soc Trans 2009; 37:569-76.
  10. Guerra L, Teter K, Lilley BN, Stenerlow B, Holmes RK, Ploegh HL, et al. Cellular internalization of cyto- lethal distending toxin: A new end to a known pathway. Cell Microbiol 2005; 7:921-34.
  11. Adams PD. Remodeling of chromatin structure in senescent cells and its potential impact on tumor sup- pression and aging. Gene 2007; 397:84-93.
  12. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, et al. Oncogene-induced senes- cence is a DNA damage response triggered by DNA hyper-replication. Nature 2006; 444:638-42.
  13. Passos JF, Saretzki G, von Zglinicki T. DNA damage in telomeres and mitochondria during cellular senes- cence: Is there a connection? Nucleic Acids Res 2007; 35:7505-13.
  14. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigen- esis. Nature 2005; 436:725-30.
  15. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, et al. Tumour biology: Senescence in premalignant tumours. Nature 2005; 436:642.
  16. Blagosklonny MV. Aging-suppressants: Cellular senes- cence (hyperactivation) and its pharmacologic decelera- tion. Cell Cycle 2009; 8:1883-7.
  17. Chen QM, Bartholomew JC, Campisi J, Acosta M, Reagan JD, Ames BN. Molecular analysis of H 2 O 2 - induced senescent-like growth arrest in normal human fibroblasts: p53 and Rb control G 1 arrest but not cell replication. Biochem J 1998; 332:43-50.
  18. Lobrich M, Shibata A, Beucher A, Fisher A, Ensminger M, Goodarzi AA, et al. gammaH2AX foci analy- sis for monitoring DNA double-strand break repair: strengths, limitations and optimization. Cell Cycle 2010; 9:662-9.

Cited by

Sorted by citations

See all 283

Metadata

Authors
Kosar, M., Bartkova, J., Hubackova, S., Hodny, Z., Lukas, J., & Bartek, J.
Affiliations
Danish Cancer Society (DK)
Venue
Cell Cycle
Published
2011-02
Volume
10
Issue
3
Pages
457-468
ISSN
  • 1538-4101 (ISSN-L)
  • 1551-4005
OpenAlex
W2083176422
Cited by
283
References
61
Citations by year
2026: 4 · 2025: 8 · 2024: 8 · 2023: 14 · 2022: 13 · 2021: 20 · 2020: 17 · 2019: 15 · 2018: 17 · 2017: 21 · 2016: 29 · 2015: 27 · 2014: 23 · 2013: 30 · 2012: 27
FWCI
19.63
Type
journal article
Language
en
Open access
Locations
  • Cell Cycle (publishedVersion)
  • PubMed (publishedVersion)
  • ASEP (submittedVersion, public-domain)
  • Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, other-oa)
Funders
  • European Commission
  • National Research Foundation
  • Danmarks Grundforskningsfond
  • Grantová Agentura České Republiky (GAP301/10/1525, AV 0Z5039906, GA301/08/0353)
  • Novo Nordisk
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
Keywords
cellular senescence, senescence-associated heterochromatin foci, replicative senescence, oncogene-induced senescence, p16INK4a, genotoxic stress, telomere shortening, cytolethal distending toxin, keratinocytes, fibroblasts, precancerous lesions, histone H3K9 trimethylation, tumor suppression
MeSH terms
Bacterial Toxins, Cell Line, DNA Damage, Heterochromatin, Humans, Genes, ras, Cellular Senescence, Cyclin-Dependent Kinase Inhibitor p16, Cell Proliferation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review